冠状动脉微血管功能障碍患者的循环α-Klotho较少
Nadia Akhiyat1, Ilke Ozcan1, Rajiv Gulati1
1Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA.
Journal of the American Heart Association
|April 19, 2024
概括
低水平的衰老蛋白Klotho可能表明冠状动脉微血管功能障碍 (CMD),一种与血管衰老相关的疾病. 这一发现表明,Klotho可能是心血管疾病早期迹象患者的生物标志物和治疗标.
科学领域:
- 心脏病学 心脏病学
- 老年学是指老年学的学科.
- 血管生物学 血管生物学
背景情况:
- 冠状动脉微血管功能障碍 (CMD) 是冠状动脉血管衰老的早期指标.
- 克洛托 (α-klotho) 是一种与生理衰老相关的循环蛋白.
- 该研究调查了低Klotho作为CMD但没有冠状动脉疾病的患者血管衰老的标志物.
研究的目的:
- 为了确定低Klotho水平是否与冠状动脉微血管功能障碍 (CMD) 有关.
- 探索Klotho作为血管衰老的生物标志物在没有显著冠状动脉疾病的患者中的潜力.
- 评估Klotho水平,内皮前体细胞和CMD之间的关系.
主要方法:
- 侵袭性冠状动脉微血管和内皮功能测试在接受胸痛血管造影的患者身上进行.
- 冠状动脉疾病是由冠状动脉对乙胆或冠状动脉血流储量的反应来定义的.
- 循环内皮原生细胞和血Klotho水平分别使用流动细胞计和ELISA进行了分析.
主要成果:
- 患有CMD的患者与没有CMD的患者相比,Klotho水平显著降低 (P=0.03).
- 低Klotho是CMD的显著预测因素,即使在调整传统心血管风险因素 (OR,0.80;P=0.05) 之后也是如此.
- 高Klotho水平与内皮前体细胞数量的增加相关,这表明血管再生潜力增强.
结论:
- 克洛托可以作为一种有价值的生物标志物,用于识别冠状动脉微血管功能障碍 (CMD).
- 克洛托为控制血管衰老和心血管疾病提供了潜在的治疗标,特别是在缺乏传统心血管风险因素的患者中.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.3K
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
2.4K
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422